AptarGroup Inc ATR
News
Aptar’s Nasal Unidose System to Deliver neffy® (epinephrine nasal spray), the First and Only FDA-Approved Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
Daniel Ackerman Named Aptar’s Chief Accounting Officer
Aptar CFO, Robert (Bob) Kuhn, Has Decided to Step Down After 37 Years with the Company
Aptar Reports Second Quarter 2024 Results
Aptar Increases Quarterly Dividend by Nearly 10% Due to Continued Strong Performance